According to a recently published research report, increasing selenium content in diets during the lactation period of calves can help dairy cows to increase their productivity and increase their production efficiency in the future. The results of this study are consistent with what we know about the synergy of selenium and vitamin E. This also demonstrated for the first time the beneficial effect of selenium on dairy cow production. Ziprasidone Intermediates
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
Ziprasidone Intermediates Ziprasidone Intermediates,Cas 7716-66-7 ,Cas 2634-33-5,Ziprasidone Hydrochloride Intermediate Nanjing Sunshine Biotech Co., Ltd , http://www.sunshine-bio.com
This study was initiated by the Slovak Animal Production Research Institute. Studies have shown that increasing the content of organic selenium in the diet of dairy cows can increase the animal's immunity, reduce the number of somatic cells in milk, and improve milk quality. The study was immediately welcomed by many dairy farmers. Many dairy farmers have long been subject to higher milk hygiene standards, but have been punished for not meeting the standards for milk quality. Moreover, the study showed that increased selenium content can reduce the incidence of mastitis in dairy cows.
Ziprasidone is a medication of the atypical antipsychotic type. It is used for the treatment of schizophrenia as well as acute mania and mixed states associated with bipolar disorder. Its intramuscular injection form is approved for acute agitation in people with schizophrenia. Ziprasidone is also used off-label for depression, bipolar maintenance, and posttraumatic stress disorder.
Ziprazidone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia as well as acute mania and mixed states associated with bipolar disorder. Its intramuscular injection form is approved for acute agitation in schizophrenic patients for whom treatment with just ziprasidone is appropriate.
We produce a series of complete intermediates for Ziprasidone, intermediate I (CAS No. 2634-33-5) and intermediate II (CAS No. 7716-66-7) etc.
